NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer 
based on integrated gene network analysis

Chen,Changxian; Hu,Yanling; Li,Li

doi:10.3892/mmr.2015.4556

NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis

Authors:
- Changxian Chen
- Yanling Hu
- Li Li
View Affiliations

Affiliations: Department of Gynecological Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Bioinformatics, Medical Research Center, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: November 11, 2015 https://doi.org/10.3892/mmr.2015.4556
Pages: 188-196
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug resistance (MDR) in epithelial ovarian cancer (EOC) remains a public health issue for women worldwide, and its molecular mechanisms remain to be fully elucidated. The present study aimed to predict the potential genes involved in MDR, and examine the mechanisms underlying MDR in EOC using bioinformatics techniques. In the present study, four public microarray datasets, including GSE41499, GSE33482, GSE15372 and GSE28739, available in Gene Expression Omnibus were downloaded, and 11 microRNAs (miRNA; miRs), including miR‑130a, miR‑214, let‑7i, miR‑125b, miR‑376c, miR‑199a, miR‑93, miR‑141, miR‑130b, miR‑193b* and miR‑200c, from previously published reports in PubMed were used to perform a comprehensive bioinformatics analysis through gene expression analysis, signaling pathway analysis, literature co‑occurrence and miRNA‑mRNA interaction networks. The results demonstrated that the expression of neuropilin 1 (NRP1) was upregulated, thereby acting as the most important hub gene in the integrated gene network. NRP1 was targeted by miR‑130a and miR‑130b at the binding site of chromosome 10: 33466864‑3466870, which was involved in the axon guidance signaling pathway. These results suggested that alteration of the gene expression levels of NRP1 expression may contribute to MDR in EOC. These data provide important information for further experimental investigations of the drug resistance‑associated functions of NRP1 in EOC.

View Figures

View References

1	Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L and Sant M; Eurocare Working Group: Survival for ovarian cancer in Europe: The across-country variation did not shrink in the past decade. Acta Oncol. 51:441–453. 2012. View Article : Google Scholar : PubMed/NCBI
2	Corney DC and Nikitin AY: MicroRNA and ovarian cancer. Histol Histopathol. 23:1161–1169. 2008.PubMed/NCBI
3	Matsuda A and Katanoda K: Five-year relative survival rate of ovarian cancer in the USA, Europe and Japan. Jpn J Clin Oncol. 44:1962014. View Article : Google Scholar : PubMed/NCBI
4	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
5	Samrao D, Wang D, Ough F, Lin YG, Liu S, Menesses T, Yessaian A, Turner N, Pejovic T and Mhawech-Fauceglia P: Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Transl Oncol. 5:469–474. 2012. View Article : Google Scholar
6	Rubin SC, Randall TC, Armstrong KA, Chi DS and Hoskins WJ: Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 93:21–24. 1999. View Article : Google Scholar : PubMed/NCBI
7	Lin H and Changchien CC: Management of relapsed/refractory epithelial ovarian cancer: Current standards and novel approaches. Taiwan J Obstet Gynecol. 46:379–388. 2007. View Article : Google Scholar
8	Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Noske A, Weichert W, Buckendahl AC, Budczies J, Müller BM, Elwali NE, Dietel M and Denkert C: Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology. 54:657–666. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zong C, Wang J and Shi TM: MicroRNA 130b enhances drug resistance in human ovarian cancer cells. Tumour Biol. 35:12151–12156. 2014. View Article : Google Scholar : PubMed/NCBI
10	Jung HJ and Suh Y: MicroRNA in aging: From discovery to biology. Curr Genomics. 13:548–557. 2012. View Article : Google Scholar :
11	Okamura K, Phillips MD, Tyler DM, Duan H, Chou YT and Lai EC: The regulatory activity of microRNA* species has substantial influence on microRNA and 3′UTR evolution. Nat Struct Mol Biol. 15:354–363. 2008. View Article : Google Scholar : PubMed/NCBI
12	Ro S, Park C, Young D, Sanders KM and Yan W: Tissue-dependent paired expression of miRNAs. Nucleic Acids Res. 35:5944–5953. 2007. View Article : Google Scholar : PubMed/NCBI
13	Carrington JC and Ambros V: Role of microRNAs in plant and animal development. Science. 301:336–338. 2003. View Article : Google Scholar : PubMed/NCBI
14	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
15	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
16	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
17	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
18	Pitto L, Ripoli A, Cremisi F, Simili M and Rainaldi G: microRNA(interference) networks are embedded in the gene regulatory networks. Cell Cycle. 7:2458–2461. 2008. View Article : Google Scholar : PubMed/NCBI
19	Ying H, Lv J, Ying T, Jin S, Shao J, Wang L, Xu H, Yuan B and Yang Q: Gene-gene interaction network analysis of ovarian cancer using TCGA data. J Ovarian Res. 6:882013. View Article : Google Scholar : PubMed/NCBI
20	Chen L, Xuan J, Gu J, Wang Y, Zhang Z, Wang TL and Shih IeM: Integrative network analysis to identify aberrant pathway networks in ovarian cancer. Pac Symp Biocomput. 31:422012.
21	Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I, Litwin S, Martin LP, Proia DA, Golemis EA and Connolly DC: Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res. 19:5053–5067. 2013. View Article : Google Scholar : PubMed/NCBI
22	Pan XH: Pathway crosstalk analysis based on protein-protein network analysis in ovarian cancer. Asian Pac J Cancer Prev. 13:3905–3909. 2012. View Article : Google Scholar : PubMed/NCBI
23	Schmeier S, Schaefer U, Essack M and Bajic VB: Network analysis of microRNAs and their regulation in human ovarian cancer. BMC Syst Biol. 5:1832011. View Article : Google Scholar : PubMed/NCBI
24	Perumal M, Stronach EA, Gabra H and Aboagye EO: Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3′-deoxy-3′-[18F] fluorothymidine- positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer. Mol Imaging Biol. 14:753–761. 2012. View Article : Google Scholar : PubMed/NCBI
25	Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC and Feilotter H: EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 19:912012. View Article : Google Scholar
26	Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S and Nephew KP: Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 8:342009. View Article : Google Scholar
27	Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters DJ, Bachvarov D, Plante M, Berns EM, Helleman J, Van Laere SJ and van Dam PA: Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One. 6:e224692011. View Article : Google Scholar : PubMed/NCBI
28	Edgar R, Domrachev M and Lash AE: Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar :
29	Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
30	Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
31	Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, et al: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 68:10307–10314. 2008. View Article : Google Scholar : PubMed/NCBI
32	Kong F, Sun C, Wang Z, Han L, Weng D, Lu Y and Chen G: miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci. 31:543–549. 2011. View Article : Google Scholar : PubMed/NCBI
33	Ye G, Fu G, Cui S, Zhao S, Bernaudo S, Bai Y, Ding Y, Zhang Y, Yang BB and Peng C: MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: Implications for chemoresistance. J Cell Sci. 124:359–368. 2011. View Article : Google Scholar : PubMed/NCBI
34	Cheng W, Liu T, Wan X, Gao Y and Wang H: MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 279:2047–2059. 2012. View Article : Google Scholar : PubMed/NCBI
35	Fu X, Tian J, Zhang L, Chen Y and Hao Q: Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 586:1279–1286. 2012. View Article : Google Scholar : PubMed/NCBI
36	van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, et al: miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 32:4284–4293. 2013. View Article : Google Scholar
37	Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L and Wang Z: Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol. 124:325–334. 2012. View Article : Google Scholar
38	Ziliak D, Gamazon ER, Lacroix B, Kyung Im H, Wen Y and Huang RS: Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility. Mol Cancer Ther. 11:2054–2061. 2012. View Article : Google Scholar : PubMed/NCBI
39	Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G, Shahabi S, Scambia G and Ferlini C: MiR-200c and HuR in ovarian cancer. BMC Cancer. 13:722013. View Article : Google Scholar : PubMed/NCBI
40	Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB: Prediction of mammalian microRNA targets. Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
41	Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M and Rajewsky N: Combinatorial microRNA target predictions. Nat Genet. 37:495–500. 2005. View Article : Google Scholar : PubMed/NCBI
42	Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B. 57:289–300. 1995.
43	Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al: NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res. 41(Database issue): D991–D995. 2013. View Article : Google Scholar :
44	Melaiu O, Cristaudo A, Melissari E, Di Russo M, Bonotti A, Bruno R, Foddis R, Gemignani F and Pellegrini S: Review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. Mutat Res. 750:132–140. 2012. View Article : Google Scholar
45	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar
46	Huang GW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC and Lempicki RA: DAVID bioinformatics resources: Expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 35:W169–W175. 2007. View Article : Google Scholar : PubMed/NCBI
47	Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD, Prionidis K, Dalamagas T and Hatzigeorgiou AG: DIANA miRPath v.2.0: Investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 40:W498–W504. 2012. View Article : Google Scholar : PubMed/NCBI
48	Zhang F and Drabier R: IPAD: The integrated pathway analysis database for systematic enrichment analysis. BMC Bioinformatics. 13(Suppl 15): S72012. View Article : Google Scholar : PubMed/NCBI
49	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
50	Batagelj V and Mrvar A: Pajek-Analysis and Visualization of Large Networks. Mutzel P, Jünger M and Leipert S: Graph Drawing. Lecture Notes in Computer Science. Springer Berlin Heidelberg; 2265. pp. 477–478. 2002, View Article : Google Scholar
51	Ozgur A, Vu T, Erkan G and Radev DR: Identifying gene-disease associations using centrality on a literature mined gene-interaction network. Bioinformatics. 24:i277–i285. 2008. View Article : Google Scholar : PubMed/NCBI
52	Li JH, Liu S, Zhou H, Qu LH and Yang JH: starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42(Database issue): D92–D97. 2014. View Article : Google Scholar :
53	Biedler JL and Riehm H: Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30:1174–1184. 1970.PubMed/NCBI
54	Ying H, Lv J, Ying T, Li J, Yang Q and Ma Y: MicroRNA and transcription factor mediated regulatory network for ovarian cancer: Regulatory network of ovarian cancer. Tumour Biol. 34:3219–3225. 2013. View Article : Google Scholar : PubMed/NCBI
55	Chen C, Li M, Chai H, Yang H, Fisher WE and Yao Q: Roles of neuropilins in neuronal development, angiogenesis, and cancers. World J Surg. 29:271–275. 2005. View Article : Google Scholar : PubMed/NCBI
56	Geretti E and Klagsbrun M: Neuropilins: novel targets for anti-angiogenesis therapies. Cell Adh Migr. 1:56–61. 2007. View Article : Google Scholar : PubMed/NCBI
57	Grandclement C and Borg C: Neuropilins: A new target for cancer therapy. Cancers (Basel). 3:1899–1928. 2011. View Article : Google Scholar
58	Lampropoulou A and Ruhrberg C: Neuropilin regulation of angiogenesis. Biochem Soc Trans. 42:1623–1628. 2014. View Article : Google Scholar : PubMed/NCBI
59	Beck B, Driessens G, Goossens S, Youssef KK, Kuchnio A, Caauwe A, Sotiropoulou PA, Loges S, Lapouge G, Candi A, et al: A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature. 478:399–403. 2011. View Article : Google Scholar : PubMed/NCBI
60	Jubb AM, Strickland LA, Liu SD, Mak J, Schmidt M and Koeppen H: Neuropilin-1 expression in cancer and development. J Pathol. 226:50–60. 2012. View Article : Google Scholar
61	Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, et al: Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 11:53–67. 2007. View Article : Google Scholar : PubMed/NCBI
62	Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, Bettini ML, Vogel P, Finkelstein D, Bonnevier J, et al: Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature. 501:252–256. 2013. View Article : Google Scholar : PubMed/NCBI
63	Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL and Chung GG: High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol. 39:1835–1843. 2008. View Article : Google Scholar : PubMed/NCBI
64	Staton CA, Koay I, Wu JM, Hoh L, Reed MW and Brown NJ: Neuropilin-1 and neuropilin-2 expression in the adenoma-carcinoma sequence of colorectal cancer. Histopathology. 62:908–915. 2013. View Article : Google Scholar : PubMed/NCBI
65	Piechnik A, Dmoszynska A, Omiotek M, Mlak R, Kowal M, Stilgenbauer S, Bullinger L and Giannopoulos K: The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int J Cancer. 133:1489–1496. 2013. View Article : Google Scholar : PubMed/NCBI
66	Chaudhary B, Khaled YS, Ammori BJ and Elkord E: Neuropilin 1: Function and therapeutic potential in cancer. Cancer Immunol Immunother. 63:81–99. 2014. View Article : Google Scholar
67	Baba T, Kariya M, Higuchi T, Mandai M, Matsumura N, Kondoh E, Miyanishi M, Fukuhara K, Takakura K and Fujii S: Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition. Gynecol Oncol. 105:703–711. 2007. View Article : Google Scholar : PubMed/NCBI
68	Duman-Scheel M: Deleted in colorectal cancer (DCC) path-finding: Axon guidance gene finally turned tumor suppressor. Curr Drug Targets. 13:1445–1453. 2012. View Article : Google Scholar : PubMed/NCBI
69	Ge C, Li Q, Wang L and Xu X: The role of axon guidance factor semaphorin 6B in the invasion and metastasis of gastric cancer. J Int Med Res. 41:284–292. 2013. View Article : Google Scholar : PubMed/NCBI
70	Göhrig A, Detjen KM, Hilfenhaus G, Körner JL, Welzel M, Arsenic R, Schmuck R, Bahra M, Wu JY, Wiedenmann B and Fischer C: Axon guidance factor SLIT2 inhibits neural invasion and metastasis in pancreatic cancer. Cancer Res. 74:1529–1540. 2014. View Article : Google Scholar : PubMed/NCBI
71	Sundaram MV: RTK/Ras/MAPK signaling. WormBook. 1–19. 2006.
72	Wei SQ, Sui LH, Zheng JH, Zhang GM and Kao YL: Role of ERK1/2 kinase in cisplatin-induced apoptosis in human ovarian carcinoma cells. Chin Med Sci J. 19:125–129. 2004.PubMed/NCBI
73	Li F, Meng L, Zhou J, Xing H, Wang S, Xu G, Zhu H, Wang B, Chen G, Lu YP and Ma D: Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: A role of c-Jun NH2-terminal kinase 1. Biochem Biophys Res Commun. 335:1070–1077. 2005. View Article : Google Scholar : PubMed/NCBI
74	Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K and Zhang W: Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 23:186–199. 2013. View Article : Google Scholar : PubMed/NCBI
75	Han Y, Huang H, Xiao Z, Zhang W, Cao Y, Qu L and Shou C: Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. PLoS One. 7:e527452012. View Article : Google Scholar
76	Delfino KR and Rodriguez-Zas SL: Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence. PLoS One. 8:e586082013. View Article : Google Scholar : PubMed/NCBI
77	Liu M1, Zhang X, Hu CF, Xu Q, Zhu HX and Xu NZ: MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells. Chin J Cancer. 33:285–294. 2014. View Article : Google Scholar : PubMed/NCBI
78	Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT and Nagrath D: Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 10:7282014. View Article : Google Scholar : PubMed/NCBI
79	Ibrahim FF, Jamal R, Syafruddin SE, Ab Mutalib NS, Saidin S, MdZin RR, Hossain Mollah MM and Mokhtar NM: MicroRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian. J Ovarian Res. 8:562015. View Article : Google Scholar